

Metabolomics in Cancer Research

Kalpita Mukherjee, Rupali Dhara Mitra*

Department of Food and Nutrition, Swami Vivekananda
University, Barrackpore, West Bengal, 700121

Corresponding author e-mail: rupalidm@svu.ac.in

Abstract

Metabolomics has emerged as a transformative tool in cancer research, offering insights into the altered metabolic states that drive tumor initiation, progression, and therapeutic resistance. Cancer cells exhibit profound metabolic reprogramming, including enhanced glycolysis (Warburg effect), altered lipid metabolism, and dysregulated amino acid pathways, which support their rapid proliferation and survival. By analyzing the comprehensive profile of metabolites in cells, tissues, and biofluids, metabolomics enables the identification of unique metabolic signatures associated with different cancer types and stages. Advanced analytical techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy facilitate high-resolution metabolic profiling, leading to the discovery of novel biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Furthermore, metabolomics provides critical insights into the tumor microenvironment, highlighting interactions between cancer cells and surrounding stromal or immune cells. This approach also aids in elucidating mechanisms of drug resistance, unveiling potential metabolic vulnerabilities that can be targeted for therapy. The integration of metabolomics with other omics technologies, such as genomics and proteomics, offers a systems-level understanding of cancer biology, paving the way for precision oncology. As the field continues to evolve, metabolomics holds immense promise for advancing personalized cancer treatment and improving patient outcomes.

Keywords: *Metabolomics, Cancer, Genomics, Proteomics, Drug resistance*

Introduction

Cancer is characterized by uncontrolled cell proliferation and the ability to invade surrounding tissues and metastasize to distant organs. These malignant behaviours are underpinned by distinct metabolic alterations that support rapid growth and survival in hostile environments. Metabolomics, the study of small molecules (metabolites) in cells, tissues, or biofluids, offers a window into these biochemical changes, providing a snapshot of cellular activity and phenotype. By profiling metabolites, scientists can uncover pathways that are dysregulated in cancer, leading to potential biomarkers for diagnosis, prognosis, and therapeutic targets.

Principles of Metabolomics

Metabolomics involves the systematic identification and quantification of metabolites in a biological system. These metabolites, typically less than 1 kDa in size, include amino acids, lipids, carbohydrates, and nucleotides. The metabolome reflects the end point of gene expression and protein activity, offering a dynamic snapshot of the physiological state of a cell or organism.

Two primary analytical platforms dominate metabolomic studies:

- 1. Nuclear Magnetic Resonance (NMR) Spectroscopy:** NMR provides detailed information about the structure and quantity of metabolites. It is highly reproducible and non-destructive but may lack sensitivity compared to other methods.
- 2. Mass Spectrometry (MS):** Often coupled with chromatographic techniques like gas chromatography (GC) or liquid chromatography (LC), MS offers high sensitivity and the ability to analyze a wide range of metabolites. However, it requires extensive sample preparation and method development.

Data from these platforms are processed using bioinformatics tools to identify and quantify metabolites, followed by statistical analyses to interpret the biological significance of the findings.

Metabolic Reprogramming in Cancer

Cancer cells undergo metabolic reprogramming to meet the demands of rapid proliferation and survival under stress. Key features of this reprogramming include:

- **Aerobic Glycolysis (Warburg Effect):** Even in the presence of oxygen, cancer cells preferentially convert glucose to lactate. This shift supports biosynthetic processes and alters the tumor microenvironment.
- **Glutamine Addiction:** Many tumors rely heavily on glutamine for energy production and as a carbon and nitrogen source for biosynthesis.
- **Altered Lipid Metabolism:** Enhanced lipid synthesis and uptake support membrane production and energy storage in cancer cells.
- **Reactive Oxygen Species (ROS) Management:** Cancer cells modulate ROS levels to promote signaling pathways that support growth while avoiding cytotoxicity.

These metabolic alterations are not uniform across all cancers but vary depending on tumor type, stage, and microenvironmental factors.

Metabolomic profiling has revealed distinct metabolic alterations across various cancer types, reflecting the unique biochemical demands and adaptations of different tumors. Below is a table summarizing specific metabolomic findings associated with selected cancer types:

Table 1: Metabolomic profiling in different types of cancer

Cancer Type	Key Metabolites	Reference
Liver Cancer	Altered lipid metabolism Changes in amino acid profiles	Budhu <i>et al.</i> , 2013
Pancreatic Cancer	Enhanced fatty acid synthesis Dysregulated glucose metabolism	Zhang <i>et al.</i> , 2013
Breast Cancer	Accumulation of 2-hydroxyglutarate Altered choline metabolism	Terunuma <i>et al.</i> , 2014
Ovarian Carcinoma	Elevated levels of specific amino acids and lipids Distinct metabolite patterns	Denkert <i>et al.</i> , 2006
Glioma	Accelerated anabolic metabolism Accumulation of glycolytic intermediates	Chinnaiyan <i>et al.</i> , 2012
Gastric Cancer	Upregulation of carbohydrate and amino acid metabolism pathways Specific metabolite signatures associated with tumour subtypes	Li <i>et al.</i> , 2022

Metabolomic studies have identified specific metabolites that are altered in various cancer types, reflecting the unique metabolic reprogramming associated with tumor development and progression. Below is a table summarizing key metabolites associated with selected cancers:

Table 2: Different types of metabolites in different types of cancer

Cancer Type	Key Metabolites
Gliomas	Elevated levels of 2- hydroxyglutarate (2-HG) due to IDH1/2 mutations
Renal Cell Carcinoma	Accumulation of fumarate resulting from fumarate hydratase (FH) mutations
Paranganglioma and Pheochromocytoma	Elevated succinate levels due to succinate dehydrogenase (SDH) mutations
Breast Camcer	Increased choline-containing compounds. Elevated lactate levels
Prostate Cancer	Decrease citrate levels Increased sarcosine levels

Applications of Metabolomics in Cancer Research

1. Biomarker Discovery

Identifying metabolites that are uniquely altered in cancer can lead to the development of biomarkers for early detection, prognosis, and monitoring therapeutic responses. For instance, elevated levels of 2-hydroxyglutarate have been associated with mutations in isocitrate dehydrogenase (IDH) in gliomas and acute myeloid leukemia, serving as a potential diagnostic marker.

2. Understanding Tumor Biology

Metabolomic profiling can reveal insights into tumor biology, including metabolic dependencies and vulnerabilities. For example, studies have shown that certain breast cancer subtypes exhibit distinct lipidomic profiles, suggesting potential targets for therapy.

3. Therapeutic Target Identification

By elucidating metabolic pathways that are essential for tumor survival, metabolomics can identify novel therapeutic targets. Inhibitors targeting glutaminase, an enzyme critical for glutamine metabolism, are being explored in cancers with high glutamine dependence.

4. Monitoring Treatment Response

Metabolomic changes can serve as early indicators of treatment response or resistance. For instance, alterations in phospholipid metabolites have been observed in response to chemotherapy, potentially serving as markers for therapeutic efficacy.

Challenges and Future Directions

While metabolomics holds great promise, several challenges persist:

- **Standardization:** Variability in sample collection, processing, and analysis can affect results. Establishing standardized protocols is essential for reproducibility.
- **Data Complexity:** The vast amount of data generated requires sophisticated bioinformatics tools and expertise for interpretation.
- **Integration with Other Omics:** Combining metabolomics with genomics, transcriptomics, and proteomics can provide a more comprehensive understanding of cancer biology but also adds complexity.

Future research should focus on longitudinal studies to understand metabolic changes over time, the development of non-invasive metabolomic assays (e.g., liquid biopsies), and the integration of metabolomic data with other omics and clinical information to advance personalized medicine.

The Role of Artificial Intelligence (AI) in Cancer Metabolomics

AI-driven approaches, including machine learning (ML) and deep learning (DL), have significantly enhanced metabolomic data analysis. These computational techniques offer the ability

to handle complex, high-dimensional datasets, uncover hidden patterns, and provide predictive insights (Zhang et al., 2020).

Conclusion

Metabolomics offers a powerful lens to study the complex metabolic alterations in cancer. By providing insights into tumor biology, identifying potential biomarkers, and uncovering novel therapeutic targets, metabolomics has the potential to significantly impact cancer diagnosis, prognosis, and treatment. Continued advancements in analytical technologies, data analysis, and integration with other biological data will further enhance the role of metabolomics in oncology.

References

Schmidt, D. R., & Patel, D. (2021). Metabolomics in cancer research and emerging applications in clinical oncology. *CA: A Cancer Journal for Clinicians*, 71(4), 333-358.

Jennifer L Spratlin 1, Natalie J Serkova, S Gail Eckhardt. (2009). Clinical applications of metabolomics in oncology: a review, 15;15(2):431-40

David S Wishart, Yannick Djoumbou Feunang, Ana Marcu, An Chi Guo, Kevin Liang, Rosa Vázquez-Fresno, Tanvir Sajed, Daniel Johnson, Carin Li, Naama Karu, Zinat Sayeeda, Elvis Lo, Nazanin Assempour, Mark Berjanskii, Sandeep Singhal, David Arndt, Yonjie Liang, Hasan Badran, Jason Grant, Arnau Serra-Cayuela, Yifeng Liu, Rupa Mandal, Vanessa Neveu, Allison Pon, Craig Knox, Michael Wilson, Claudine Manach, Augustin Scalbert, HMDB 4.0: the human metabolome database for 2018, *Nucleic Acids Research*, Volume 46, Issue D1, 4 January 2018, Pages D608–D617

Pandey R, Caflisch L, Lodi A, Brenner AJ, Tiziani S. Metabolomic signature of brain cancer. *Mol Carcinog*. 2017 Nov;56(11):2355-2371. doi: 10.1002/mc.22694. Epub 2017 Jul 17. PMID: 28618012; PMCID: PMC5708886.

Beger RD, et al. (2016). Metabolomics of human cancer: A review of the literature. *Metabolomics*, 12(10), 161.

Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and

emerging applications in clinical oncology. *CA Cancer J Clin.* 2021 Jul;71(4):333-358Liu X, et al. (2019). Metabolomics analysis reveals distinct metabolic profiles in breast cancer subtypes. *Sci Rep*, 9(1), 12345.

Li M, et al. (2020). Metabolomics-based biomarker discovery for early detection of lung cancer. *J Proteome Res*, 19(2), 533-544.

Xie Y, Meng WY, Li RZ, Wang YW, Qian X, Chan C, Yu ZF, Fan XX, Pan HD, Xie C, Wu QB, Yan PY, Liu L, Tang YJ, Yao XJ, Wang MF, Leung EL. Early lung cancer diagnostic biomarker discovery by machine learning methods. *Transl Oncol.* 2021 Jan;14(1):100907

Zhang, W., Li, X., Gao, H., & Sun, J. (2020). Machine learning in cancer metabolomics. *Briefings in Bioinformatics*, 21(5), 1692-1708.